Mounjaro Side Effects vs Cancer Risk UK | Cured Pharmacy

Clinically Proven UK Registered Pharmacy

Cheapest Mounjaro Side Effects UK Price £124.99

Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

WEIGHTLOSSNEW £20 off first order using code WEIGHTLOSSNEW

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check if you're eligible

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£99 £79.00

£19.75 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £99
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy Oral Pill
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy Oral Pill
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy Oral Pill
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy Oral Pill
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Comparing Mounjaro Side Effects Against Cancer Concerns

Published on: June 03, 2026

Understanding mounjaro side effects vs cancer risk uk is essential for informed treatment decisions. At Cured Pharmacy, our UK-registered clinical team provides evidence-based guidance on tirzepatide's safety profile, helping you weigh common side effects against theoretical cancer concerns based on current clinical data. All Mounjaro prescriptions require assessment by a UK prescriber and start from £124.99.

Understanding Mounjaro's Safety Profile and Cancer Risk Evidence

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities [1]. The medication's safety profile has been extensively studied across the SURPASS clinical trial programme, involving over 10,000 participants monitored for up to 72 weeks.

Regarding cancer concerns, current clinical evidence shows no increased cancer incidence in tirzepatide-treated patients compared to placebo groups [1]. The theoretical thyroid cancer risk associated with GLP-1 receptor agonists stems from rodent studies where extremely high doses caused thyroid C-cell tumours in rats and mice — a finding that has not been replicated in human clinical trials or post-marketing surveillance data [2].

The MHRA and European Medicines Agency continue to monitor long-term safety data, but no causal link between tirzepatide and human cancer has been established in clinical practice. Mounjaro carries a contraindication for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, reflecting precautionary regulatory standards rather than observed human risk [1][2].

Common Mounjaro Side Effects: What UK Patients Actually Experience

The most frequently reported side effects of Mounjaro are gastrointestinal in nature, affecting approximately 30-50% of patients during initial dose escalation [1]. These include nausea, diarrhoea, vomiting, constipation, and reduced appetite — effects directly related to tirzepatide's mechanism of slowing gastric emptying and reducing hunger signals.

In the SURPASS-1 trial, nausea occurred in 12-18% of participants depending on dose, with most cases classified as mild to moderate and diminishing significantly after the first 4-8 weeks of treatment [1]. Gastrointestinal side effects are typically managed through gradual dose escalation, taking the injection with food, staying well-hydrated, and avoiding high-fat meals.

Other common side effects include injection site reactions (redness, itching, mild swelling), fatigue during the initial adjustment period, and occasional headaches. Serious adverse events such as pancreatitis or severe hypoglycaemia are rare, occurring in less than 1% of patients in clinical trials, and are more common in those taking concurrent diabetes medications [1][3].

Managing Side Effects During Treatment

UK prescribers typically initiate Mounjaro at 2.5mg weekly for four weeks, then increase to 5mg for another four weeks before considering further escalation to therapeutic doses of 7.5mg, 10mg, 12.5mg, or 15mg [1]. This gradual titration schedule significantly reduces the severity and duration of gastrointestinal side effects whilst allowing your body to adapt to the medication's effects. Our clinical team at Cured Pharmacy provides ongoing support throughout dose adjustments, ensuring you can contact a UK pharmacist if side effects become concerning or persistent.

Mounjaro Side Effects vs Cancer Risk UK: Separating Evidence from Speculation

When comparing mounjaro side effects vs cancer risk uk, it's crucial to distinguish between common, well-documented adverse effects and theoretical risks based on animal models. Gastrointestinal side effects are common, expected, and typically resolve within weeks — these are pharmacological effects of the medication's intended mechanism [1].

Cancer risk, by contrast, remains theoretical in humans. The rodent thyroid tumour findings that prompted regulatory warnings involved doses far exceeding human therapeutic levels and occurred in species with fundamentally different thyroid C-cell biology [2]. Comprehensive meta-analyses of GLP-1 receptor agonist trials, including tirzepatide, have found no statistically significant increase in any cancer type among treated patients [4].

Post-marketing surveillance across millions of patient-years of semaglutide and liraglutide use (closely related medications) has not revealed elevated cancer incidence. The MHRA continues active pharmacovigilance for all GLP-1 therapies, and current evidence supports that the cardiovascular and metabolic benefits of these medications substantially outweigh theoretical long-term risks in appropriately selected patients [2][4].

Treatment Common Side Effects Cancer-Related Warnings Starting Price
Mounjaro (tirzepatide) Nausea, diarrhoea, vomiting, reduced appetite Contraindicated with MTC/MEN 2 history (rodent data only) From £124.99
Wegovy (semaglutide) Nausea, diarrhoea, constipation, abdominal pain Contraindicated with MTC/MEN 2 history (rodent data only) From £69.00
Saxenda (liraglutide) Nausea, vomiting, diarrhoea, constipation Contraindicated with MTC/MEN 2 history (rodent data only) From £68.00
Orlistat/Xenical Oily stools, faecal urgency, flatulence No cancer-related warnings From £32.00

Clinical Trial Data: Long-Term Safety Monitoring of Tirzepatide

The SURPASS clinical programme represents one of the most comprehensive safety databases for any weight management medication, with participants monitored for adverse events including malignancies throughout treatment and follow-up periods [1]. SURPASS-3, comparing tirzepatide against insulin degludec, followed participants for 52 weeks with rigorous adverse event reporting and independent safety monitoring committees.

Across all SURPASS trials, the incidence of treatment-emergent adverse events leading to discontinuation ranged from 4.3% to 7.1% for tirzepatide versus 2.1% to 3.4% for placebo or active comparators — primarily due to gastrointestinal effects rather than serious safety concerns [1]. No cases of medullary thyroid carcinoma were reported in any tirzepatide clinical trial participant.

Extended safety follow-up studies are ongoing, with some participants now monitored beyond three years of continuous treatment. Preliminary data from these extensions continue to show stable safety profiles with no emerging cancer signals, though definitive long-term epidemiological data will require another 5-10 years of post-marketing surveillance across diverse patient populations [3][4].

Comparative Safety: Tirzepatide vs Other Weight Loss Treatments

When compared to semaglutide (Wegovy) and liraglutide (Saxenda), tirzepatide demonstrates a similar side effect profile dominated by gastrointestinal symptoms, with slightly higher rates of nausea and vomiting at equivalent weight loss efficacy [1][4]. All three medications share the same thyroid cancer contraindication based on rodent data, but none have shown human thyroid malignancy signals in clinical practice. Orlistat-based treatments like Xenical present different side effects — primarily gastrointestinal fat malabsorption — without any cancer-related warnings but also with substantially lower weight loss efficacy in clinical trials.

Who Should Avoid Mounjaro: Contraindications and Cancer History

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. This contraindication is precautionary, based on the rodent findings rather than observed human cases, but UK prescribers strictly adhere to these MHRA-approved restrictions.

Patients with a history of other cancer types are not automatically excluded from tirzepatide treatment, but require individualised risk-benefit assessment by their prescriber. Active malignancy, recent cancer diagnosis, or ongoing cancer treatment typically warrant postponing weight loss medication until oncological treatment is complete and the patient is in stable remission [2].

Other contraindications include severe gastroparesis, inflammatory bowel disease in active flare, and pregnancy or breastfeeding. During your online consultation at Cured Pharmacy, our UK prescribers will review your complete medical history, including any personal or family cancer history, to ensure Mounjaro is clinically appropriate and safe for your individual circumstances.

Making an Informed Decision: Balancing Benefits Against Risks

For most UK patients considering Mounjaro, the decision centres on weighing substantial, evidence-based weight loss benefits against common but manageable gastrointestinal side effects [1]. In the SURMOUNT-1 trial, participants achieved average weight reductions of 15-22.5% depending on dose — outcomes associated with significant improvements in cardiovascular risk factors, sleep apnoea, joint pain, and metabolic health markers [3].

The theoretical cancer risk, whilst appropriately disclosed in regulatory materials, should be contextualised within the broader evidence base showing no human cancer signal across extensive clinical trials and real-world use. Obesity itself substantially increases risk for multiple cancer types including breast, colorectal, endometrial, and kidney cancers — making effective weight management a cancer risk reduction strategy [4].

Your UK prescriber will help you understand how Mounjaro's benefits and risks apply to your specific medical history, weight loss goals, and health priorities. At Cured Pharmacy, we ensure you have access to balanced, evidence-based information and ongoing clinical support throughout your treatment journey, with transparent pricing and the ability to pause or discontinue treatment at any time subject to medical guidance.

Accessing Mounjaro Through Cured Pharmacy

Starting Mounjaro at Cured Pharmacy begins with a free online consultation completed in under three minutes, reviewed by a UK-registered prescriber who will assess your suitability based on BMI, medical history, and weight loss goals. If approved, your prescription is dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), with discreet delivery to your address. Ongoing prescriber support is included, allowing you to discuss side effects, dose adjustments, or any cancer-related concerns that arise during treatment.

Scientific References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
  2. Bezin, J., Gouverneur, A., Pénichon, M., et al. (2023). GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care, 46(2), 384–390. https://doi.org/10.2337/dc22-1148 [accessed 13 August 2026]
  3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
  4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro is a prescription-only medicine that must be prescribed following consultation with a UK clinician who will assess your suitability based on your individual medical history and weight management goals.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Does Mounjaro cause cancer in humans?
Current clinical evidence shows no increased cancer incidence in humans treated with Mounjaro. The thyroid cancer warning is based on rodent studies using extremely high doses, and no cases of medullary thyroid carcinoma have been reported in clinical trials involving over 10,000 participants.
What are the most common Mounjaro side effects in UK patients?
The most common side effects are gastrointestinal: nausea (12-18% of patients), diarrhoea, vomiting, constipation, and reduced appetite. These typically occur during initial dose escalation and diminish significantly after 4-8 weeks of treatment.
Can I take Mounjaro if I have a family history of cancer?
Most cancer family histories do not contraindicate Mounjaro use. The only absolute contraindication is personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will assess your specific family history during consultation.
How does Mounjaro's cancer risk compare to Wegovy or Saxenda?
All three medications (Mounjaro, Wegovy, Saxenda) share the same precautionary thyroid cancer contraindication based on rodent data, but none have demonstrated increased cancer risk in human clinical trials or post-marketing surveillance.
What should I do if I experience severe side effects on Mounjaro?
Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, signs of pancreatitis, or allergic reactions. At Cured Pharmacy, you can reach our UK clinical team for guidance on managing side effects or adjusting your treatment plan.
Is the mounjaro side effects vs cancer risk uk concern based on real evidence?
The cancer concern is based on precautionary rodent studies, not human evidence. Real-world side effects like nausea and diarrhoea are common and well-documented, whilst no human cancer link has been established in clinical trials or ongoing pharmacovigilance.
How long does it take for Mounjaro side effects to improve?
Most gastrointestinal side effects peak during the first 4-8 weeks of treatment and diminish substantially as your body adapts to the medication. Gradual dose escalation, as prescribed by UK clinicians, significantly reduces side effect severity and duration.
Does obesity itself increase cancer risk more than Mounjaro?
Yes. Obesity is an established risk factor for multiple cancer types including breast, colorectal, endometrial, and kidney cancers. Effective weight management through medications like Mounjaro may reduce overall cancer risk by addressing obesity-related inflammation and metabolic dysfunction.
Does Mounjaro side effects vs cancer risk uk data show increased cancer rates?
Current UK and global clinical trial data do not show that Mounjaro increases cancer risk in humans. Thyroid tumours observed in rodent studies have not been confirmed in human patients, and ongoing pharmacovigilance continues to monitor long-term safety. Cured Pharmacy provides full prescriber consultations to discuss your individual risk factors.
Are Mounjaro side effects worse than the cancer risk reported in studies?
Common Mounjaro side effects like nausea, vomiting, and diarrhoea are temporary and manageable, whereas no confirmed cancer risk has been established in humans. The benefits of significant weight loss and improved metabolic health typically outweigh these transient side effects. Cured Pharmacy's UK prescribers review your full medical history before prescribing.
Should I stop Mounjaro if I'm worried about cancer risk in the UK?
You should not stop Mounjaro without consulting a healthcare professional, as there is no confirmed human cancer risk. If you have concerns about thyroid cancer history or other risk factors, discuss them with your prescriber during your consultation. Cured Pharmacy offers ongoing clinical support to address any safety concerns throughout your treatment.
How does the MHRA monitor Mounjaro cancer risk and side effects in the UK?
The MHRA continuously monitors all reports of side effects and potential long-term risks, including cancer, through the Yellow Card scheme. Mounjaro has been approved for use in the UK after rigorous safety assessments, and any new safety signals are investigated promptly. Cured Pharmacy follows all MHRA guidance and keeps patients informed of any updates.
Can I claim Mounjaro side effects compensation if cancer risk becomes confirmed?
If future evidence confirms a cancer link, patients may have legal recourse, but currently no such link has been established in human trials. All medications carry some level of risk, which is why thorough prescriber assessments are essential before starting treatment. Cured Pharmacy ensures every patient receives a full consultation and ongoing monitoring throughout their Mounjaro journey.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 13 August 2026

Last updated on 13 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 13 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (13 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.